The LACE study group
Effect of perindopril or leucine on physical performance in older people with sarcopenia: the LACE randomized controlled trial
The LACE study group; Achison, Marcus; Adamson, Simon; Akpan, Asangaedem; Aspray, Terry; Avenell, Alison; Band, Margaret M; Bashir, Tufail; Burton, Louis A; Cvoro, Vera; Donnan, Peter T; Duncan, Gordon W; George, Jacob; Gordon, Adam L.; Gregson, Celia L; Hapca, Adrian; Henderson, Emily; Hume, Cheryl; Jackson, Thomas A; Kemp, Paul; Kerr, Simon; Kilgour, Alixe; Lyell, Veronica; Masud, Thair; McKenzie, Andrew; McKenzie, Emma; Patel, Harnish; Pilvynte, Kristina; Roberts, Helen C; Rossios, Christos; Sayer, Avan A; Smith, Karen T; Soiza, Roy L; Steves, Claire J; Struthers, Allan D; Sumukadas, Deepa; Tiwari, Divya; Whitney, Julie; Witham, Miles D
Authors
Marcus Achison
Simon Adamson
Asangaedem Akpan
Terry Aspray
Alison Avenell
Margaret M Band
Tufail Bashir
Louis A Burton
Vera Cvoro
Peter T Donnan
Gordon W Duncan
Jacob George
ADAM GORDON Adam.Gordon@nottingham.ac.uk
Professor of The Care of Older People
Celia L Gregson
Adrian Hapca
Emily Henderson
Cheryl Hume
Thomas A Jackson
Paul Kemp
Simon Kerr
Alixe Kilgour
Veronica Lyell
Thair Masud
Andrew McKenzie
Emma McKenzie
Harnish Patel
Kristina Pilvynte
Helen C Roberts
Christos Rossios
Avan A Sayer
Karen T Smith
Roy L Soiza
Claire J Steves
Allan D Struthers
Deepa Sumukadas
Divya Tiwari
Julie Whitney
Miles D Witham
Abstract
BACKGROUND: This trial aimed to determine the efficacy of leucine and/or perindopril in improving physical function in older people with sarcopenia. METHODS: Placebo-controlled, parallel group, double-blind, randomized two-by-two factorial trial. We recruited adults aged≥70years with sarcopenia, defined as low gait speed (<0.8m/s on 4m walk) and/or low handgrip strength (women<20kg, men<30kg) plus low muscle mass (using sex and body mass index category-specific thresholds derived from normative UK BioBank data) from 14 UK centres. Eligible participants were randomized to perindopril 4mg or placebo, and to oral leucine powder 2.5g or placebo thrice daily. The primary outcome was the between-group difference in the short physical performance battery (SPPB) score over 12-month follow-up by repeated-measures mixed models. Results were combined with existing systematic reviews using random-effects meta-analysis to derive summary estimates of treatment efficacy. RESULTS: We screened 320 people and randomized 145 participants compared with an original target of 440 participants. For perindopril [n=73, mean age 79 (SD 6), female sex 39 (53%), mean SPPB 7.1 (SD 2.3)] versus no perindopril [n=72, mean age 79 (SD 6), female sex 39 (54%), mean SPPB 6.9 (SD 2.4)], median adherence to perindopril was lower (76% vs. 96%; P<0.001). Perindopril did not improve the primary outcome [adjusted treatment effect -0.1 points (95%CI -1.2 to 1.0), P=0.89]. No significant treatment benefit was seen for any secondary outcome including muscle mass [adjusted treatment effect -0.4kg (95%CI -1.1 to 0.3), P=0.27]. More adverse events occurred in the perindopril group (218 vs. 165), but falls rates were similar. For leucine [n=72, mean age 78 (SD 6), female sex 38 (53%), mean SPPB 7.0 (SD 2.1)] versus no leucine [n=72, mean age 79 (SD 6), female sex 40 (55%), mean SPPB 7.0 (SD 2.5)], median adherence was the same in both groups (76% vs. 76%; P=0.99). Leucine did not improve the primary outcome [adjusted treatment effect 0.1 point (95%CI -1.0 to 1.1), P=0.90]. No significant treatment benefit was seen for any secondary outcome including muscle mass [adjusted treatment effect -0.3kg (95%CI -1.0 to 0.4), P=0.47]. Meta-analysis of angiotensin converting enzyme inhibitor/angiotensin receptor blocker trials showed no clinically important treatment effect for the SPPB [between-group difference -0.1 points (95%CI -0.4 to 0.2)]. CONCLUSIONS: Neither perindopril nor leucine improved physical performance or muscle mass in this trial; meta-analysis did not find evidence of efficacy of either ACE inhibitors or leucine as treatments to improve physical performance.
Citation
The LACE study group, Achison, M., Adamson, S., Akpan, A., Aspray, T., Avenell, A., …Witham, M. D. (2022). Effect of perindopril or leucine on physical performance in older people with sarcopenia: the LACE randomized controlled trial. Journal of Cachexia, Sarcopenia and Muscle, 13(2), 858-871. https://doi.org/10.1002/jcsm.12934
Journal Article Type | Article |
---|---|
Acceptance Date | Jan 17, 2022 |
Online Publication Date | Feb 16, 2022 |
Publication Date | Apr 4, 2022 |
Deposit Date | Jan 20, 2022 |
Publicly Available Date | Jan 20, 2022 |
Journal | Journal of Cachexia, Sarcopenia and Muscle |
Print ISSN | 2190-5991 |
Electronic ISSN | 2190-6009 |
Publisher | Wiley Open Access |
Peer Reviewed | Peer Reviewed |
Volume | 13 |
Issue | 2 |
Pages | 858-871 |
DOI | https://doi.org/10.1002/jcsm.12934 |
Keywords | Physiology (medical); Orthopedics and Sports Medicine |
Public URL | https://nottingham-repository.worktribe.com/output/7280979 |
Publisher URL | https://onlinelibrary.wiley.com/doi/10.1002/jcsm.12934 |
Additional Information | Authors belong to the LACE study group. |
Files
J cachexia sarcopenia muscle - 20...formance in older people with
(774 Kb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Developing the principles of chair based exercise for older people: a modified Delphi study
(2014)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search